Citius Oncology, Inc.
NASDAQ:CTORDrug Manufacturers - General
+$0.03 today
- Market cap
- $51.83M
- Beta
- 3.42
- P/E (TTM)
- -1.6
- EPS (TTM)
- -$0.42
Volume 0.15M
Average 0.12M
CTOR Net Debt
Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.
Citius Oncology, Inc.NASDAQ: CTOR
Net Debt · Q2 FY2026 · quarter ended Mar 2026
Net debt falls 69.3% from a year ago
Net debt stood at $1.17M at the end of Q2 FY2026, down 69.3% from a year earlier and up 133.4% from the prior quarter.
Context
- Net debt amounted to 1.2% of total assets at the end of Q2 FY2026, down 3.0 pp from a year earlier.
- Net debt increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether net debt keeps falling in the next quarterly balance sheet after a -69.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Debt history
USD · from the balance sheet
- Latest · FY2025
- (124.8K) USD
- Year-over-year change
- -103.3%
| Period | Period end | Net Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | (124.8K) | -103.3% |
| FY2024 | 2024-09-30 | 3.8M | — |
| FY2023 | 2023-09-30 | 0 | — |
| FY2022 | 2022-09-30 | 0 | — |
Net Debt vs competitors
How CTOR compares with its peers on the latest reported figures
- CTOR's Mar 2026 net debt of $1.17M is the 4th highest of the 10 companies compared; the peer median is -$9.92M.
- Its year-over-year change of -69.3% is the 7th highest of 10, against a peer median of -19.4%.
- Net debt amounts to 1.2% of total assets for CTOR, versus a peer median of 35.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $103.01M | +188.5% | — | 35.1% | |
| Mar 2026 | $50.67M | +65.0% | — | 43.1% | |
| Mar 2026 | $37.22M | -3.1% | -13.4% | 13.1% | |
CTORCitius Oncology, Inc. | Mar 2026 | $1.17M | -69.3% | — | 1.2% |
ACTUActuate Therapeutics Inc | Mar 2026 | -$7.73M | -98.7% | — | 86.7% |
| Mar 2026 | -$9.92M | +41.9% | — | 15.0% | |
| Mar 2026 | -$22.24M | -822.1% | — | 25.6% | |
| Mar 2026 | -$53.66M | -19.4% | — | 90.9% | |
| Mar 2026 | -$58.22M | -27.0% | — | 86.6% | |
| Mar 2026 | -$166.93M | -766.5% | — | 32.9% | |
| Peer median (excluding CTOR) | -$9.92M | -19.4% | -13.4% | 35.1% | |
Competitors are the stored peer set for CTOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Citius Oncology, Inc.
NASDAQ:CTOR
Intrinsic Alpha fair value
Locked
Current Price
$0.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.